Mylan debuts innovative version of levetiracetam

US generic drugmaker Mylan (Nasdaq: MYL) says that its Mylan Institutional business has launched Levetiracetam in Sodium Chloride Injection, 500mg/100mL, 1,000mg/100mL and 1,500mg/100mL, for intravenous use.

Mylan's launch of this new product, which has been approved by the US Food and Drug Administration, marks the first time that multiple strengths of premixed levetiracetam, the active ingredient of Belgian drugmaker UCB’s Keppra, will be supplied in ready-to-administer bags of sodium chloride injection (100mL). This product is an antiepileptic drug indicated for certain types of seizures, says Mylan.

Mylan chief executive Heather Bresch said: "The launch of this product is another example of Mylan's commitment to deliver new and innovative products to our institutional customers. We are excited to be the first and only company to offer three strengths of Levetiracetam in ready-to-administer bags, which assist in the ease, accuracy and convenience of dosing. The launch reflects our commitment to innovate to meet unmet needs and our strategy of expanding Mylan's product portfolio across the generic, specialty and niche market segments."